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Abstract  
Purpose of review: To review some aspects of the relationship between epilepsy and 
depression that have recently received increasing attention and may become major research 
topics in the near future. 
Recent findings: Epidemiological studies show that depression and suicide are, in some 
cases, premorbid symptoms preceding the onset of the epilepsy. Suicide is also three times 
more frequent in epilepsy than in the general population. Reliable screening instruments for 
depression and suicidality in patients with epilepsy are now available but data from real life 
clinical settings are needed in order to develop shared clinical pathways between neurology 
and psychiatry. Data in children with epilepsy are still limited although it is well known that, 
outside epilepsy, almost 50% of adult patients with mood and anxiety disorders have a 
previous history during childhood. Despite increasing attention to the problem, the additional 
stigma associated with mental health problems still represents one of the major barriers to 
prompt diagnosis and treatment.  
Summary: New studies will focus on the development of shared clinical pathways between 
neurology and psychiatry for mood disorders and suicide prevention. New global campaigns 
on the double stigma will support this process in areas where psychiatric comorbidities are 
still underdiagnosed and undertreated.   
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Introduction  
The mutual relationships among epilepsy, seizures and mood disorders have been 
recognised for a long time, fascinating generations of clinicians and neuroscientists [1]. In his 
famous quotations, Hippocrates stated that “melancholics ordinarily become epileptics, and 
epileptics, melancholics: what determines the preference is the direction the malady takes; if 
it bears upon the body, epilepsy, if upon the intelligence, melancholy” [2]. Epilepsy is now 
recognized as a disorder of the brain characterized not only by an enduring predisposition to 
generate epileptic seizures, but explicitly also by the neurobiological, cognitive, 
psychological, and social consequences of this condition [3]. The new definition of epilepsy 
clearly highlights the importance of identifying and addressing behavioural problems of 
patients with epilepsy as these manifestations represent an integral part of the disease.  
Mood disorders represent the most frequently encountered psychiatric comorbidities in 
patients with epilepsy [4] and are associated with poor quality of life (QoL )[5], seizure 
severity [6], side effects of AEDs [7], drug-resistance [8] and a poor outcome after epilepsy 
surgery [9]. However, mood disorders are, more often than not, ignored, unless they are 
severe enough to cause major problems or disability. This is due to multiple factors, including 
the patients’ reluctance to volunteer spontaneously information about  mental health issues,  a 
paucity (or total lack) of a specific training of the treating neurologist to recognize these 
psychiatric comorbidities and  a lack of time in very busy clinics to screen for them. During 
last few years, clinicians became increasingly interested in psychiatric comorbidities of 
epilepsy and screening instruments for mood [10] and anxiety disorders [11] are now 
available. In addition, epidemiological studies are now showing that some patients develop a 
complex neuropsychiatric condition characterised by depressive symptoms and recurrent 
seizures. This is a narrative review of some aspects of the relationship between epilepsy and 
depression that will probably receive increasing attention in the near future based on recent 
published data and new findings. Key references were identified through PubMed searches 
between 2011 and 2016 using the terms “epilepsy” and “depression”. Additional publications 
were hand searched if relevant for the discussion. 
 
Depression as a premorbid condition 
A number of studies are now suggesting that depression can be per se associated with 
an increased risk of epilepsy. Data from the General Practice Research Database show that 
the incidence-rate ratio of depression is significantly higher in the three years preceding the 
onset of epilepsy [12]. A population-based study in Sweden shows that the age-adjusted odds 
ratio for the development of epilepsy is 2.5 for patients with a depressive disorder [13]. Other 
three population-based studies confirm that patients with a depressive disorder have a three to 
seven times increased risk to develop epilepsy [14,15][16]. A previous meta-analysis of 
Phase II and Phase III placebo-controlled trials of antidepressant drugs between 1985 and 
2004 showed that subjects randomised to antidepressants other than clomipramine and 
bupropion are 69% less likely to develop seizures and patients randomised to placebo are 19 
times more likely to have seizures as compared to the expected incidence in the general 
population [17]. All these evidence taken together clearly suggest that some patients with 
depression develop epilepsy as part of the “natural course” of the depressive disorder or that 
depression may represent a premorbid phase of some epileptic syndromes.  
In terms of neurobiological mechanisms, despite a large number of studies investigating the 
neurobiological links between epilepsy and depression, the clear basis for the development of 
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epilepsy in patients with depressive disorders is not fully clarified. It is well-known that 
depression and temporal lobe epilepsy share a disruption in the same brain networks but this 
is obviously not enough to explain the observed associations and, most importantly, the 
observed temporal sequences. Basic neuroscientists formulated a number of hypotheses 
mainly based on data from animal models. Low serotonin levels have been historically 
described in mood disorders but it seems now evident that they are present in epilepsy as 
well. In fact, similar findings are reported in animal models of epilepsy such as genetically 
epilepsy-prone rates [18], pilocarpine status epilepticus model in Wistar rats [19] and Rhesus 
monkeys [20]. It is still unclear whether there is a specific threshold in serotonin loss leading 
from depression to spontaneous seizures and which serotoninergic pathway is more likely to 
be responsible for this transition. Interestingly, a deletion of the 5HTC2 receptor subunit 
lowers the threshold for audiogenic seizures in mouse models of epilepsy [21] but further 
studies are needed.  
Another coming area of research looking at the biological mechanisms shared by epilepsy 
and depression is that of stress. In reality, this is not entirely new as the role of the 
hypothalamic–pituitary–adrenal (HPA) axis in depression is well established. However, it is 
now evident that pretreatment with corticosterone accelerates the kindling process in rats [22] 
and this would be in keeping with the emerging literature on the potential role of stress in 
epilepsy [23]*** not only as a precipitant factor but also as a potential causative one [24]. 
The disruption in GABA and glutamate neurotransmissions used to be a classic finding in 
epilepsy but cumulative data are now showing similar findings in depression through a HPA 
mediated mechanism. In fact, steroids can modulate the expression and composition of 
GABA-A receptors promoting epileptogenesis and increasing brain excitability in general 
[25,26]**. As a result, GABA hypofunction is now also reported in patients with depression 
[27] and NMDA receptor antagonists are now tested not only as antiepileptic agents but also 
as antidepressants [28].  
Advances in the neurobiology and molecular pharmacology of the relationship between 
depression and epilepsy are bringing into the epilepsy field neurochemical pathways, such as 
serotonin and melatonin, traditionally investigated for mood disorders, and completely new 
biological targets such as galanin receptors [29]. Nalutozan is a selective 5HT1A agonist 
currently under investigation for both anxiety and epilepsy while beprodone is a melatonin 
type 3 receptor agonist under Phase IIb development in drug-refractory localisation-related 
epilepsies [29]. Galanin is one of the most inducible neuropeptides and its biosynthesis is 
increased 2 to 10-fold upon seizure activity in the brain. Agonists of Galanin receptor type 2 
seem to have both anticonvulsant and analgesic/anxiolytic properties and a specific agonist 
(Nax 810-2) [4] is currently under preclinical investigation. 
 
Depression and anxiety in children 
Depression has been historically studied and investigated in the context of adult 
epilepsies.  However, in the general population, anxiety disorders are much more common in 
children than in adults [30,31]. Diagnosis and management of mood and anxiety disorders in 
children have important implications. In fact, children with anxiety disorders seem to be at 
increased risk of further psychiatric comorbidities such as attention deficit hyperactivity 
disorder (ADHD) or conduct disorder [32]. In addition, half of adults with depression had a 
history of anxiety before the age of 15 [33]. For all these reasons, the American Academy of 
Child and Adolescent Psychiatry has recommended that children and adolescents are 
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routinely screened for symptoms of anxiety [34]. It seems, thus, evident that both a careful 
assessment and a prompt treatment of depression and anxiety in children with epilepsy would 
prevent the development of major psychiatric disorders during adulthood.   
Epidemiological studies of depression in children with epilepsy are still limited compared to 
the large number of publications in adults. A long-term prospective study in newly diagnosed 
children with epilepsy followed up for up to 9 years, reported a 13% prevalence of depression 
[35]. A large US nationwide survey found depression in 8% of children with current epilepsy, 
7% of children with a previous history of seizures and 2% of controls [36] and similar figures 
were reported by a UK community-based study of children with epilepsy 5-15 years of age 
attending schools in Sussex [37]. Anxiety and depression seem to be more common in 
children with epilepsy and lower IQ, language delays or decreasing scores on 
neuropsychological assessment [38–40]. As already mentioned, children with anxiety are at 
increased risk of ADHD and it is now established that this is 2 to 3 times more frequent in 
epilepsy as compared to the general population [41]. In addition, a community-based survey 
in more than 1000 adult patients with epilepsy reported that ADHD-like symptoms are 
present in 1 out of 5 subjects and are associated with depression, anxiety, drug-resistance and 
poor quality of life [42]. The importance of ADHD should not be underestimated as it is a 
well-known risk factor for major psychiatric problems during adulthood such as alcohol and 
substance abuse, psychiatric hospitalisations and antisocial personality disorder [43]. All 
these evidence taken together suggest that some children with epilepsy can develop a 
complex neuropsychiatric condition characterised by mood and anxiety as well as cognitive 
and neurodevelopmental problems and this seems to be evident in children with even subtle 
neurological signs or cognitive problems. In fact, neurotypical (normal neurologic, cognitive, 
and imaging examinations) young adults with childhood-onset epilepsy do not present 
increased rates of psychiatric disorders [44].  
But the relationship between depression and epilepsy in children is even more complex than 
that as many psychological factors are implicated as compared to adults. Dunn et al. found 
that the adolescent attitude towards the epilepsy and an external or unknown locus of control 
were predictors of depression [45]. The adverse effect of seizures on the family, limited 
emotional support, poor communication, inadequate support of child autonomy and maternal 
depression contribute to anxiety and depression in the child with epilepsy [45–47]. It is, 
therefore, evident that, apart from neurobiological variables, social variables, stigma and 
parental attitudes play a relevant role in mood and anxiety disorders in children with epilepsy. 
For all these reasons, tailored treatment approaches are needed and should include 
multidisciplinary approaches including psychotherapy, occupational and vocational therapy. 
In addition, the role of perceived stigma will receive increasing attention in prevention and 
management of mood disorders in children with epilepsy.  
 
Reducing mortality of epilepsy: suicide prevention 
While suicide represents 1% of all deaths in the general population, it accounts for 
11.5% of all deaths in epilepsy. These figures are not so different from those of SUDEP that 
accounts for 18% of all deaths in epilepsy. However, as compared to SUDEP, suicide is still 
an unmentionable issue in epilepsy. Standard mortality ratio for suicide in patients with 
epilepsy is three times higher than the general population [48] and such a risk remains high 
even after excluding those with a history of psychiatric disorders and adjusting for 
socioeconomic factors [49]. A population-based study in England has shown that 25% of 
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patients with epilepsy have a lifetime history of suicidal thoughts and more than 10% have a 
lifetime history of suicidal attempts [50]. Similar figures have been reported by another 
population-based study from Canada [51]. Several studies have attempted to identify reasons 
for such an increased risk. Historically, suicide has been linked to temporal lobe epilepsy [52] 
but more recent data failed to find such a close association [53]. Severity of the seizure 
disorder does not seem to be a relevant factor [54] while depression is, at present, the major 
risk factor [55,56]. It is likely that other, still unknown, biological factors contribute to the 
increased risk of suicide in epilepsy [57] given the bidirectional relationship between epilepsy 
and depression [12,16]. In fact, a recent study identified an association between suicide 
attempts and epilepsy even before the onset of seizures themselves, and independently of 
psychiatric disorders [58]**.  
As already mentioned, suicide in epilepsy has long represented, and probably still represents, 
a taboo. In fact, if we analyse the whole literature on suicide in epilepsy, 50% of currently 
available indexed papers have been published in the ten years, while the remaining 50% in 
the preceding 30- 40 years [59]. The interest on suicide in epilepsy rapidly escalated during 
last few years and the US Food and Drug Administration (FDA) alert on the increased risk of 
suicidal ideation and behaviour in people taking antiepileptic drugs (AEDs) has probably 
contributed to that [60]. The FDA meta-analysis focused on multicentre-randomised placebo 
controlled trials of 11 AEDs. Spontaneously reported suicidality occurring during double-
blind trials with an AED (or within one day of stopping) were sought and categorized.  
Results suggested an increased suicidality risk in patients taking AEDs. The FDA results 
were received with great scepticism by clinicians and professional societies [61]. Some 
investigators questioned the validity of FDA findings, identifying serious methodological 
flaws [62]. However, there is no doubt that the FDA document has finally highlighted the 
issue of suicide in epilepsy. An expert consensus statement developed by an ad-hoc task force 
of the Commission on Neuropsychobiology of the International League Against Epilepsy 
(ILAE) stressed the need for screening instruments of suicide and clinical monitoring during 
clinical trials of AEDs [63].  
Prevention is the only treatment for suicide but research on screening for suicide in epilepsy 
is still at a very early stage. The Columbia Suicide Severity Rating Scale (CSSRS) [64] is 
currently recommended to identify and monitor patients at high suicidality risk in clinical 
trials of AEDs [63]. It is available in several languages, and a validity study in epilepsy was 
published [65]. However, it is rather unrealistic to consider the CSSRS as a user-friendly 
clinical instrument to use in routine clinical practice for screening purposes. A cross sectional 
study compared the CSSRS, administered either in-person or using an Interactive Voice 
Response System (E-CSSRS) against the MINI, and showed good to excellent psychometric 
properties [65].  However, both the E-CSSRS and the MINI are time consuming and have to 
be administered by a trained health professional, becoming not cost-effective. Other authors 
suggested the use of item 9 of the Beck Depression Inventory [56] but the validity and 
psychometric properties of this method have never been investigated. The Neurological 
Disorders Depression Inventory for Epilepsy (NDDIE) was developed for the rapid and 
objective detection of a major depressive episode in patients with epilepsy [10]. It has shown 
to be a very practical and user-friendly screening instrument in any outpatient or inpatient 
setting. The NDDIE is now available in a number of languages and many clinicians are 
becoming increasingly familiar with this screening tool in their clinical practice. A recent 
study validated the use of item 4 of the NDDIE as a suicidality screening instrument, showing 
good psychometric properties [66]. Suicide may be considered an unmentionable issue by 
many neurologists, as they may feel uncomfortable in asking the patient directly. However, 
according to the NICE guidelines, suicidal ideation and intent should always be part of the 
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assessment of depression. The NDDIE as a rapid suicidality-screening instrument represents 
an easy and straightforward way to introduce the issue of suicide in a busy epilepsy clinic, by 
simply asking the patient why he or she has answered in that way item 4, and whether he or 
she already has a plan. This will also stimulate epilepsy centres to develop shared care 
pathways with liaison psychiatric services in order to assess whether the person has adequate 
social support and is aware of sources of help; to arrange help appropriate to the level of risk; 
and to advise the person to seek further help if the situation deteriorates. In fact, it is 
important to bear in mind that, aside from the already mentioned barriers, reporting suicide 
ideation or behaviours may be affected by complex and often conflicting cultural attitudes 
[67]. In May 2013, the 66
th
 World Health Assembly adopted the first-ever Mental Health 
Action Plan of the World Health Organization (WHO) of which suicide prevention is an 
integral part, with the goal of reducing the rate of suicide in countries by 10% by 2020 [68]. 
The epilepsy community should not lose this opportunity and should support the dialog 
between neurology and psychiatry services in the development of effective suicide prevention 
strategies in order to reduce mortality of patients with epilepsy.  
 
Double stigma in epilepsy: the new challenge 
The increasing attention to psychiatric comorbidities of epilepsy is bringing to light 
the issue of double stigma. In fact, the stigma associated with mental health problems 
combined to that of epilepsy probably represents a major barrier to prevention and treatment 
of depression and suicide in epilepsy, especially in some geographic areas. Interestingly 
enough, no studies investigated the issue of double stigma in epilepsy even if it is well-known 
in other medical conditions, for example obesity and mental health [69] or HIV and mental 
health [70].  
Stigma towards epilepsy is present in both high-income and poor-resources countries [71] 
and plays a role in mood and anxiety problems in both people with epilepsy and their 
caregivers [72]. In low and middle income countries, 20% of mothers of children with 
epilepsy feel stigmatized because of their child's neurological condition [73] and the 
caregiver's perception of burden, together with the level of family function, are indirectly 
correlated with depressive symptoms in people with epilepsy via the mediating effect of 
caregiver depression [74]. In high-income countries, social aspects of stigma are also 
important determinants of anxiety and depression in epilepsy [75]. In fact, stigma can affect 
the more intimate life domains of people such as cohabitation and marriage. Patients with 
epilepsy are less likely to be married and patients suffering from the enacted stigma are 
significantly more likely to get divorced in comparison with people with other chronic 
medical conditions [76,77][78]. The US Centers for Disease Control and Prevention, 
Epilepsy Program, pointed that, in US, one in five patients with epilepsy lives alone and less 
than one in four lives in households with two adults and children [79]. Adults with epilepsy 
living alone may be at increased risk of injury associated with uncontrolled seizures, mood 
disorders and mental health issues associated with social isolation and early mortality due to 
SUDEP or suicide.  
Persistent stigma around mental health issues is one of the key barriers to the treatment of 
depression, especially in ethnic minorities [80]. For example, data from the STAR*D trial 
show that, in US, Hispanics initiate anti-depressant medication treatment at a much lower rate 
than whites, and are more likely to discontinue their treatment without consulting their 
physician [81]. In the general population, common concerns about depression treatments 
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include fears about the addictive and harmful properties of antidepressants, worries about 
taking too many pills, and the stigma attached to taking psychotropic medications. It is easy 
to figure out the impact of these concerns in patients with epilepsy with, in addition, the 
general belief that antidepressant can potentially lower the seizure threshold. 
The double stigma associated with epilepsy and mental health problems clearly has a 
negative impact on prevention and care efforts. It creates a context in which patients are 
reluctant to acknowledge mental health issues, and has strong psychological consequences for 
those who have uncontrolled epilepsy, increasing social isolation and depression. Addressing 
stigma and discrimination in health care systems and the wider community should be an 
essential part of epilepsy care [82]*. In poor resource countries, stigma directly affects access 
to health care [83,84] but living in a high-income country with better health system 
performance and higher health expenditure per capita does not necessarily lead to a reduction 
in perceived discrimination, unless the public health system invests in awareness programmes 
to increase public knowledge and reduce stigma [85]. Depressive symptoms and poor social 
supports have the greatest impact on reported felt stigma in people with epilepsy [86]. It is 
evident that any program dedicated to the prevention and treatment of psychiatric problems in 
epilepsy has to consider stigma and related factors. People living with epilepsy should be 
centrally involved in policy formation and service delivery. Their involvement in the 
planning and delivery of mental health support will similarly contribute to the development 
of relevant services, including peer-led initiatives, and can empower them by building self-
esteem, decreasing isolation, and enabling openness about epilepsy and mental health issues. 
They can be become involved in a number of ways, including policy-making and strategic 
planning, formation of support groups, counselling programs, positive living courses, and 
inclusion in the training of mental health professionals. Double stigma means double 
challenge and for this reason it becomes even more important to invest energies and 
resources. Further robust data collection and surveillance to identify points of intervention are 
urgently needed.  
 
Conclusion 
 It is now recognised that patients with epilepsy may present with a complex 
neuropsychiatric syndrome accompanied by depression and purpose-developed screening 
instruments are now available. However, data on prevention and early diagnosis are still 
lacking. Data on children will be of great value for the development of clinical pathways for 
early diagnosis of depression and suicide prevention. In fact, further studies on suicide will be 
of great value in order to reduce mortality in epilepsy. Suicide prevention has finally become 
the goal of a new WHO strategy and this is an important opportunity to further implement the 
management of patients at high risk such as people with epilepsy. Overcoming stigma and 
fighting against the double stigma of epilepsy and mental disorders will be the new challenge.  
 
Key points: (3-5 bullet points) 
Epidemiological studies suggest that depression may represent a premorbid phase in some 
patients with epilepsy 
Double stigma probably represents a relevant barrier to diagnosis and treatment of mood 
disorders in epilepsy but no data is available 
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Up to 13% of children with epilepsy suffer from depression but this seems to be more 
common in those with lower IQ, language delays or decreasing scores on neuropsychological 
assessment 
Suicide represents 11.5% of all causes of death in epilepsy, being three times more frequent 
than in the general population 
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